Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Urological research

• Publication date

  2002-09-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00240-002-0275-0PMID 12389114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth factors in bladder cancer

  2004cited by this paper
• The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.

  2001cited by this paper
• Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM‐46228

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Radiotherapy for Carcinoma of the Bladder: A Review

  2001cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• The Farnesyltransferase Inhibitor L 744 , 832 Reduces Hypoxia in Tumors Expressing

  2001cited by this paper
• Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

  2001cited by this paper
• Current status of clinical trials of farnesyltransferase inhibitors

  2001cited by this paper
• Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation

  2001cited by this paper
• Adenovirus‐mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H‐ras mutant

  2001cited by this paper
• Tyrosine kinase inhibitors—ZD1839 (Iressa)

  2001cited by this paper
• Treatment of metastatic urothelial cancer in the post-MVAC era

  2001cited by this paper
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  2001cited by this paper
• Significance of the Grb2 and Son of Sevenless (Sos) Proteins in Human Bladder Cancer Cell Lines

  2000cited by this paper
• Mutation of cell cycle regulators and their impact on superficial bladder cancer.

  2000cited by this paper
• Ras and Rho GTPases: a family reunion.

  2000cited by this paper
• Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells.

  2000cited by this paper
• Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

  2000cited by this paper
• A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

  2000cited by this paper
• Signal transduction by the JNK group of MAP kinases.

  2000influential reference
• H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

  2000cited by this paper
• Signaling—2000 and Beyond

  2000cited by this paper
• Essential role for oncogenic Ras in tumour maintenance

  1999cited by this paper
• Growth inhibition of human pancreatic cancer cell lines by anti‐sense oligonucleotides specific to mutated K‐ras genes

  1999cited by this paper
• Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells

  1999cited by this paper
• Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y

  1998cited by this paper
• Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression.

  1998cited by this paper
• p120 GAP Modulates Ras Activation of Jun Kinases and Transformation*

  1997cited by this paper
• The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

  1997cited by this paper
• Proliferation of human malignant astrocytomas is dependent on Ras activation

  1997cited by this paper
• The significance of Ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines.

  1997cited by this paper
• Screening of H‐ras Gene Point Mutations in 50 Cases of Bladder Carcinoma

  1997cited by this paper
• Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma

  1997cited by this paper
• Oncoprotein Networks Review

  1997cited by this paper
• Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.

  1996cited by this paper
• Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation*

  1996cited by this paper
• Increased expression of the Ras suppressor Rsu-1 enhances Erk-2 activation and inhibits Jun kinase activation

  1996cited by this paper
• Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation

  1996cited by this paper
• Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS

  1996influential reference
• Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.

  1996cited by this paper
• Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.

  1996cited by this paper
• Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.

  1995cited by this paper
• Protein modules and signalling networks

  1995cited by this paper
• Suppression of various human tumor cell lines by a dominant negative H-ras mutant.

  1994cited by this paper
• Urinary bladder cancer: mechanisms of development and progression.

  1994cited by this paper
• SH2/SH3 signaling proteins.

  1994cited by this paper
• JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.

  1994cited by this paper
• Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK.

  1994cited by this paper
• Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway.

  1994cited by this paper
• Overexpression of the Grb2 gene in human breast cancer cell lines.

  1994cited by this paper
• Epidermal‐growth‐factor‐receptor expression is associated with rapid tumor proliferation in bladder cancer

  1994cited by this paper
• Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.

  1993cited by this paper
• Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms.

  1993cited by this paper
• Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation

  1993cited by this paper
• Proteins regulating Ras and its relatives

  1993cited by this paper
• Membrane-anchored growth factors.

  1993cited by this paper
• The function of GRB2 in linking the insulin receptor to Ras signaling pathways.

  1993cited by this paper
• Screening of human bladder tumors and urine sediments for the presence of H‐ras mutations

  1993cited by this paper
• Oncogenic Activation of Ras Proteins

  1993cited by this paper
• Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor.

  1993cited by this paper
• The MAP kinase cascade is essential for diverse signal transduction pathways.

  1993cited by this paper
• Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells

  1993cited by this paper
• Inhibition of SDC25 C-domain-induced guanine-nucleotide exchange by guanine ring binding domain mutants of v-H-ras.

  1993cited by this paper
• The pathway to signal achievement

  1993cited by this paper
• Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.

  1993cited by this paper
• Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing.

  1993cited by this paper
• Mammalian Ras interacts directly with the serine/threonine kinase Raf.

  1993cited by this paper
• Function and regulation of ras.

  1993influential reference
• Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro

  1993cited by this paper
• Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas.

  1992cited by this paper
• Epidermal growth factor receptor and bladder cancer: a review.

  1992cited by this paper
• Molecular cloning of cDNAs encoding a guanine-nucleotide-releasing factor for Ras p21

  1992cited by this paper
• Function of Ras as a molecular switch in signal transduction.

  1992cited by this paper
• Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors.

  1992cited by this paper
• H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts.

  1991cited by this paper
• The GTPase superfamily: conserved structure and molecular mechanism

  1991cited by this paper
• Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.

  1990cited by this paper
• The ras superfamily of small GTP-binding proteins.

  1990cited by this paper
• trans-Dominant suppressor mutations of the H-ras oncogene.

  1990cited by this paper
• Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Human bladder and colon carcinomas contain activated ras p21

  1989cited by this paper
• KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

  1988cited by this paper
• Genetic alterations during colorectal-tumor development.

  1988cited by this paper
• Clonal heterogeneity, experimental metastatic ability, and p21 expression in H-ras-transformed NIH 3T3 cells.

  1988cited by this paper
• Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

  1988cited by this paper
• ras genes.

  1987cited by this paper
• Cellular ras activity and tumor cell proliferation.

  1987cited by this paper
• Normal and activated ras oncogenes and their encoded products

  1986cited by this paper
• ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma

  1985cited by this paper
• Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors.

  1985cited by this paper
• Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue

  1983cited by this paper
• Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

  1982cited by this paper
• Homologous radioimmunoassay for human epidermal growth factor (urogastrone).

  1978cited by this paper

• Optimizing drug combinations for human bladder carcinoma using genetic algorithm based on network analysis

  2025cites this paper
• Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy

  2024cites this paper
• Correlation between Pin1 and Bladder Cancer

  2022cites this paper
• Pathogenesis of Urothelial Carcinoma

  2022cites this paper
• Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer

  2020cites this paper
• Reduction of mitomycin C resistance in human bladder cancer T24 cells by knocking-down ras oncogene

  2018cites this paper
• Curcumin Enhances Chemosensitivity and Apoptosis in T24 Bladder Cancer Cells through Inhibition of the Ras/ MAPK Signaling Pathway

  2018cites this paper
• Mutational Analysis of FGFR3 and HRAS Genes in Bladder Cancer and Washing Cell Sediments of Moroccan Patients

  2015cites this paper
• Notch-1 regulates proliferation and differentiation of human bladder cancer cell lines by inhibiting expression of Krüppel-like factor 4.

  2014cites this paper
• Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells.

  2014cites this paper
• H-ras Mutation Detection in Bladder Cancer by COLD-PCR Analysis and Direct Sequencing

  2012cites this paper
• Y27632 attenuates the aristolochic acid-promoted invasion and migration of human urothelial cancer TSGH cells in vitro and inhibits the growth of xenografts in vivo.

  2012cites this paper
• Non-Muscle-Invasive Low- and High-Grade Neoplasia

  2012cites this paper
• Evidence-based Anticancer Materia Medica for Bladder Cancer

  2012cites this paper
• Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population.

  2010cites this paper
• The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells.

  2010cites this paper
• Bladder cancer

  2009cites this paper
• H-ras and c-fos exhibit similar expression patterns during most stages of oral oncogenesis.

  2008cites this paper
• Cancer urothéliaux métastatiques : le futur et les perspectives

  2008cites this paper
• Mutations of RAS gene family in specimens of bladder cancer.

  2008cites this paper
• [Metastases from urothelial carcinoma : future and prospects].

  2008cites this paper
• Deregulation of the Hox Gene Network and Cancer

  2007cites this paper
• LOXL 1 and LOXL 4 Are Epigenetically Silenced and Can Inhibit Ras / Extracellular Signal-Regulated Kinase Signaling Pathway in Human Bladder Cancer

  2007cites this paper
• Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA‐damaging drug etoposide markedly increases apoptosis

  2007cites this paper
• LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.

  2007cites this paper
• Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis

  2007cites this paper
• Gene expression profiling of chemically induced rat bladder tumors.

  2007cites this paper
• Choline kinase: an important target for cancer.

  2006cites this paper
• Genistein-induced proteome changes in the human endometrial carcinoma cell line, ishikawa

  2006cites this paper
• Developing innovative strategies for advanced transitional cell carcinoma of the bladder

  2006cites this paper
• Solution structure of an oncogenic mutant of Cdc42Hs.

  2006cites this paper
• Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine.

  2004cites this paper
• From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.

  2004influential citation
• Overexpression of H-ras and pERK 1/2 Related to Lymph Node Metastasis in Oral Squamous Cell Carcinomas

  2003cites this paper
• Perioperative Chemotherapy in Advanced Bladder Cancer – Part II: Adjuvant Treatment

  2003cites this paper
• Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas

  2003cites this paper
• Perioperative Chemotherapy in Advanced Bladder Cancer: Part I Neoadjuvant Treatment

  2003cites this paper